MNLP – Refresher final assessment

Time limit: 0

Quiz-summary

0 of 15 questions completed

Questions:

Information

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You have to pass the previous Module’s quiz in order to start this quiz:

Results

Quiz complete. Results are being recorded.

Results

0 of 15 questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Congratulations on completing the Refresher Final Assessment.

We will be in touch shortly about your certificate.

Answered
Review

Question 1 of 15

1. Question
1 point(s)
According to the 2014 IMWG revised diagnostic criteria additional myeloma defining events include:
- A. Clone bone marrow plasma cell percentage > 40%
- B. Involved/uninvolved SFLC ration> 100 with involved SFLC > 100 mg/L
- C. At least two focal lesions greater than 7 mm in size
- D. Involved/uninvolved SFLC ration> 100 with involved SFLC > 75 mg/L
- E. Involved/uninvolved SFLC ration> 80 with involved SFLC > 100 mg/L
Correct

Incorrect
Question 2 of 15

2. Question
1 point(s)
Use some of these words to complete the following sentence.

show, asymptomatic, symptomatic, avoided, have no, used, 30%, 50%, 60%, 70%
- Smouldering myeloma is also known as , a term that is recommended to be . Smouldering myeloma is now diagnosed if the percentage of clonal bone marrow plasma cells is less than and patients myeloma defining events.
Correct

Incorrect

Question 3 of 15

3. Question

1 point(s)

Choose right answers

Sort elements

FDG PET-CT
Whole body low-dose CT
Skeletal survey
Whole body magnetic resonance imaging (MRI)

is particularly recommended for newly diagnosed non-secretory myeloma patients.

also has the advantage of demonstrating extramedullary disease.

is the standard imaging technique for patients with suspected or newly diagnosed myeloma

is recommended as the first choice imaging technique

Correct

Incorrect

Question 4 of 15

4. Question
1 point(s)
Which of the following statements about hyperdiploid in myeloma is true.
- A. It is associated with more aggressive forms of myeloma.
- B. It has a higher incidence of myeloma bone disease.
- C. It affects around 70% of patients.
- D. It involves chromosomal translocations.
Correct

Incorrect
Question 5 of 15

5. Question
1 point(s)
According to the cytogenetic risk stratification of myeloma.
- A. Trisomies are indicators of high risk myeloma.
- B. Deletions affecting the p53 tumour suppressor gene are associated with intermediate risk myeloma.
- C. The median overall survival of high risk patients is around three years.
- D. The median overall survival of standard risk patients is greater than ten years.
- E. The majority of newly diagnosed myeloma patients fall into the standard risk category.
Correct

Incorrect
Question 6 of 15

6. Question
1 point(s)
Which of the following statements about the revised international staging system (R-ISS) is correct.
```
Choose one.
```
- A. The R-ISS now incorporates the impact of high-risk cytogenetics and elevated serum albumin levels.
- B. Among the high risk cytogenetic abnormalities are the presence of del(17p) and t(11;14).
- C. The R-ISS is as robust prognostic tool as the previously used ISS.
- D. Elevated levels of lactate dehydrogenase (LDH) are associated with the more aggressive disease.
- E. The R-ISS is also used to inform treatment decisions.
Correct

Incorrect
Question 7 of 15

7. Question
1 point(s)
Which of the following statements about minimal residual disease (MRD) in myeloma is true.
```
Choose one.
```
- A. Monitoring MRD has become the standard of care in myeloma.
- B. The serum FLC assay can detect the presence of MRD.
- C. Among the currently available techniques for detecting MRD, the most sensitive one is multiparametric flow cytometry.
- D. When MRD is undetectable using highly sensitive methods, this is linked to better patient outcomes.
- E. Additional categories related to complete response are immunophenotypic and cellular complete responses.
Correct

Incorrect
Question 8 of 15

8. Question
1 point(s)
Which side effects become less common when Bortezomib is subministered subcutaneously rather than intravenously?
```
Choose one.
```
- A. Venous thromboembolism
- B. Diarrhoea
- C. Peripheral Neuropathy
- D. Dizziness
Correct

Incorrect
Question 9 of 15

9. Question
1 point(s)
Which of the following statements is true about Lenalinomide myeloma-related treatment?
```
Choose one.
```
- A. Lenalidomide was first licensed for use in combination with dexamethasone for newly diagnosed myeloma patients.
- B. Lenalidomide is now licensed in Scotland and Wales as a monotherapy maintenance treatment for newly diagnosed patients who have undergone high-dose therapy and autologous stem cell transplantation (HDT-ASCT).
- C. The dose of lenalidomide should not be altered since treatment will become ineffective.
- D. Lenalidomide is approved in Europe in combination with melphalan and dexamethasone for newly diagnosed transplant-ineligible patients followed by monotherapy maintenance treatment.
- E. Lenalidomide is approved in Scotland and Wales in combination with dexamethasone for newly diagnosed transplant-ineligible patients.
Correct

Incorrect
Question 10 of 15

10. Question
1 point(s)
Choose the true statements.
- A. Pomalidomide belongs to a class of drugs known as proteasome inhibitors.
- B. The Myeloma XI trial is testing the efficacy of a three drug-combination: carfilzomib, cyclophosphamide and dexamethasone as induction treatment.
- C. Ixazomib is the first oral proteasome inhibitor to be used in myeloma.
- D. Panobinostat belongs to a class of drugs known as histone deacetylases.
- E. Pomalidomide is not currently available for myeloma patients through the NHS.
Correct

Incorrect
Question 11 of 15

11. Question
1 point(s)
Choose from the following words to complete the sentences.

Immunotherapy, CAR-T cell therapy, proteasome inhibitors, virotherapy
Daratumumab, Elotuzumab, Pembrolizumab, Isatuximab, Indatuximab ravtansine
CD38, CD138, PD-1, PD-L1, SLAMF7
T cells, B cells, lymphocytes, plasma cells, natural killer cells
- A. The term includes various treatments including that of monoclonal antibodies.
  
  B. and are monoclonal antibody therapies that have been approved by the European Medicines Agency for treating myeloma patients.
  
  C. Daratumumab is designed to target .
  
  D. Checkpoint inhibition allows to recognise and destroy myeloma cells.
Correct

Incorrect
Question 12 of 15

12. Question
1 point(s)
Select the following true statements.
- A. A type of CAR-T cell therapy for myeloma patients has recently been approved in the US.
- B. A specific CAR-T cell therapy targets multiple different proteins on myeloma cells.
- C. A CAR-T cell therapy targeting a protein known as BCMA is currently under investigation.
- D. An advantage of CAR-T cell therapies is the long-term duration of responses.
- E. A disadvantage of CAR-T cell therapy is the immune-related toxicity.
Correct

Incorrect
Question 13 of 15

13. Question
1 point(s)
Select the following true statements.
- A. Monoclonal antibody treatments rely on creating long-term memory of a myeloma patient’s immune system.
- B. Reolysin is a type of vaccine that is trialed for treating myeloma patients.
- C. MUK eleven is a clinical trial which involves a type of oncolytic virus therapy.
- D. Oncolytic virus therapy relies exclusively on the use of natural viruses that are harmless to humans.
Correct

Incorrect
Question 14 of 15

14. Question
1 point(s)
Select the following true statements.
- A. Today more than half of myeloma patients live for 10 years or longer.
- B. Extended myeloma survival is associated with a cumulative burden of disease and an impairment of patients’ quality of life.
- C. One of the five main points of the National Cancer Survivorship Initiative involves using patient-reported outcome measures with regards to care and support.
- D. Pain and fatigue are among the physical late effects of myeloma.
- E. Myeloma patients have an increased risk of developing a second primary malignancy late in life.
Correct

Incorrect
Question 15 of 15

15. Question
1 point(s)
Which of the following statements is true about the health-related quality of life (HRQoL) of myeloma patients?
```
Choose one answer
```
- A. HRQoL refers exclusively to the negative aspects due to disease and treatment effects.
- B. HRQoL is an objective phenomenon.
- C. Patient-reported outcomes are reports produced by patients with input from the healthcare team.
- D. MyPOS is a type of patient-reported outcome measure.
- E. MyPOS main focus is assessing myeloma patients’ information needs and satisfaction about their healthcare.
Correct

Incorrect

MNLP – Refresher final assessment